MAPT and Alzheimer disease: Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework Neurobiol Aging Neurobiol Aging 2017 2017 52 52 196 196 213 213 10.1016/j.neurobiolaging.2016.02.034 10.1016/j.neurobiolaging.2016.02.034 28317649 28317649